Developing new drugs is time-consuming and expensive. DelMar Pharma researches old drugs and establishes new IP around them to streamline the process. LSIPR spoke to chief executive Jeffrey Bacha about the company’s approach.
There has been much debate about whether there is a global deterioration of IP, and many commentators would suggest that India is leading the charge. Andrew Jenner and Ernest Kawka reflect on the experiences of innovative biopharmaceutical companies in India.
A decision from an opposition division of the European Patent Office may have “far-reaching consequences” for US patent holders, Solveig Moré tells LSIPR.
In 1990, the Human Genome Project began its quest to identify every gene in the human genome. Now, Spiral Genetics can sequence a human genome in three hours. LSIPR spoke to Spiral Genetics’ chief executive Adina Mangubat to find out how the company protects its IP.
At some offices, the passage of a patent through the system is not quite as fast as applicants might hope—and at others it may be quicker than they would like. Matt Smith and Jonathan Wills outline the situation.
Danish firm Bavarian Nordic has a portfolio of patents for vaccines and cancer treatments, but likes to keep some of its cards close to its chest, as LSIPR finds out.
Gabriel Di Blasi outlines the existing impediments to developing new biotechnology products in Brazil, and considers recent efforts to improve the situation.
As support for the study of rare diseases picks up, how does a good IP strategy bring orphan drugs to market? LSIPR spoke to aTyr Pharma’s chief executive John Mendlein to find out.
The European Patent Office grants approximately 6,000 biotechnology patents per year. LSIPR spoke to Victor Kaas, director of biotechnology at the office, about how it faces the unique challenges of the industry.
The law of patents and SPCs has yet to be tested in the context of medicines which can be used to treat specific groups of patients, as Paul England explains.